Index

Note: Page numbers with prefix ‘f’ refers to figures and ‘t’ refers to tables.

A
abdominal organs
  MRI applications in, 215, 215f, 216f
acquisition matrix, 91
acquisition parameter modification
  in motion artifact reduction, 126–7, 127f, 128f
actively shielded gradient coil, 184
ADC. See analog-to-digital converter (ADC)
advanced imaging applications, 147–61. See also specific types, e.g.,
diffusion, 147–53, 148f, 150f, 152f
diffusion-weighted imaging–related, 151–3
fMRI, 156–7
noble gas imaging, 159–61, 160f
perfusion, 153–5, 154f–6f
ultra-high field imaging, 158–9
AET. See Applications Entity Title (AET)
agitated patients
  MRI in, 221
aliasing, 105, 107–8, 107f–10f
amplitude
  in RV waveform characterization, 40
analog-to-digital converter (ADC), 12–13
Applications Entity Title (AET), 180
arterial spin labeling (ASL)
  continuous, 153
  in perfusion studies, 153
  pulsed, 153
artifact(s), 103–25. See also specific types, e.g., motion artifacts
  “blooming,” 120
chemical shift, 108–111, 109f, 111f, 111r
coherece, 113, 115–17, 115f–18f
described, 103
diffusion-weighted imaging, 151–3
external, 119–25
flow misregistration, 104, 105f, 106f
magnetic susceptibility difference, 117, 118f, 120–1, 121f
motion, 103–5, 105f, 106f
phase cancellation, 110–11, 111f, 111r
radial, 119, 120f
sequence protocol–related, 105, 107–19
truncation, 112, 112f–14f
ASL. See arterial spin labeling (ASL)
atom
  structure of, 2

B
b value
  in diffusion, 148
base magnetic field
  safety precautions related to, 197
benzoxypropionic tetraacetate (BOPTA)
  in MRI, 191
black-blood MRA techniques, 135
BLADE, 134, 134f
“blooming” artifact, 120
BOLD fMRI studies, 157
Bolzmann distribution, 7
BOPTA. See benzoxypropionic tetraacetate (BOPTA)
bowel
  MRI applications in, 215, 215f
brain
  MRI applications in, 203, 203f, 204f
breast
  MRI applications in, 209–10
bright-blood MRA images, 145, 146f
Brownian motion, 147
bulk magnetic susceptibility, 8–9

C
Carr–PURcell–Meiboom–Gill (CPMG) technique, 184
CASL. See continuous arterial spin labeling (CASL)
center frequency
  in RV waveform characterization, 40
cerebral ischemia
  diffusion-weighted imaging in evaluation of, 151–3
chemical shift
  in MR, 14–16, 15f, 16f
  in MRS, 162–4, 163f, 164f
chemical shift artifacts, 108–10, 109f
  of second kind, 110–11, 111f, 111r
chemical shift imaging (CSI), 169
chronic kidney disease (CKD)
classification of, 193, 193r
CKD. See chronic kidney disease (CKD)
clinical applications, 200–21
  abdominal organs, 215, 215f, 216f

Brian M. Dale, Mark A. Brown and Richard C. Semelka.
© 2015 John Wiley & Sons, Ltd. Published 2015 by John Wiley & Sons, Ltd.
clinical applications (continued)
  brain, 203, 203f, 204f
  breast, 209–10
  common bile duct, 215, 216f
  for ETSE, 220
  examination design considerations in, 202
  general principles of, 200–2
  great vessels, 210–11, 211f, 212f
  heart, 210–11, 211f, 212f
  kidneys, 215, 216f
  knee, 207f, 208f
  liver, 211–15, 213f, 214f
  musculoskeletal, 206, 207f–9f
  neck, 204–5
  for out-of-phase gradient echo, 219
  pelvis, 215, 217f, 217f, 218f
  in sedated or agitated patients, 221
  shoulder, 209f
  for single-echo spin echo sequence, 218–19
  specific sequences and clinical situations,
    218–21
  spine, 205–6, 205f, 206f
  for spoiled gradient echo, 219
  for standard multiecho spin echo, 220
  for T1-weighted techniques, 218–20
  fat saturation, 219–20
  for T2-weighted techniques, 220–1
  fat saturation, 221
  thorax, 206–9
  coherence artifacts, 113, 115–17, 115f–18f
  coil(s)
    actively shielded gradient, 184
    phased-array, 58–9, 60f, 61f
    surface, 59, 60f
  common bile duct
  MRI applications in, 215, 216f
  composite pulses, 44–5, 45f
  computer systems
    in MRI system, 177–80, 178f, 187f
    continuous arterial spin labeling (CASL), 153
    continuous wave (CW) mode operation
    in RF selective excitation, 39–44, 41f–3f
    contrast agents, 189–95
    advantages of, 189
    adverse reactions to, 192–3, 193f
    BOPTA in, 191
  categorization of, 189
  Feridex, 194–5
  GBCAs, 190–3, 191f, 192r–3r
  intravenous agents, 190–5, 191f, 192r–3r, 194f
  negative agents, 195
  oral agents, 195
  safety precautions related to, 199
  T1 relaxation agents, 190–3, 191f, 192r–3r
  T2 relaxation agents, 194–5, 194f
  contrast-to-noise ratio, 91
  CPMG technique. See Carr–Purcell–Meiboom–Gill
    (CPMG) technique
  crosstalk, 89–90, 90f
  cryogen(s)
    described, 197
  safety precautions related to, 197–8
  CSI. See chemical shift imaging (CSI)
  CW. See continuous wave (CW)

D
  data acquisition system
    in MRI system, 178f, 186–8
  data collection methods, 54–5, 54f–6f
  demodulated signal, 13–14
  DICOM (digital imaging and communications in
    medicine), 179–80
  DICOM Service Class Uses and Service Class
    Provider, 180
  diffusion, 147–53, 148f, 150f, 152f
    defined, 147
    described, 147–8, 148f
    measurements of, 148–9
  diffusion-weighted imaging
    applications of, 151–3
  digital imaging and communications in medicine
    (DICOM), 179–80
  directional dependence
    in diffusion measurement, 149–50, 152f
  Dixon method
    for fat suppression, 102, 102f
    duration
    in RV waveform characterization, 40

E
  echo planar imaging (EPI) sequences, 75–7, 76f
    MP pulses incorporated into, 82–5, 83f–5f
  echo spacing, 88
  echo time (TE), 87–8, 88f
  echo train inversion recovery sequence, 79f, 80
  echo train length, 88
  echo train spin echo (ETSE), 69–70, 69f
    clinical applications for, 220
    encoding
      phase, 33–5, 33f, 34f
      energy absorption
        macroscopic, 10, 11f
        microscopic, 10, 11f
    EPI sequences. See echo planar imaging (EPI)
      sequences
  ETSE. See echo train spin echo (ETSE)
  excitation
    RF
      in MR, 10–12, 11f
      RF selective, 39–44, 41f–3f
    excitation angle, 88
    excitation order
crosstalk and, 89–90, 90f
    described, 90
  external artifacts, 119–25
    described, 119
    magnetic field distortions, 120–2, 121f, 122f
    magnetic susceptibility difference artifact, 120–1, 121f
    measurement hardware, 122–4
    noise, 123f–4f, 124–5
extrinsic parameters, 89–91, 90f
  effects of, 92t
  variables in, 93
extrinsic variables, 93

F
fat saturation techniques
  T1-weighted
    clinical applications for, 219–20
  T2-weighted
    clinical applications for, 221
FDA. See Food and Drug Administration (FDA)
Feridex
  in MRI, 194–5
  ferumoxides, 194–5, 194f
FID. See free induction decay (FID)
field of view (FOV), 91
FLAIR. See fluid-attenuated inversion recovery (FLAIR)
flip angle, 88
flow compensation
  in motion artifact reduction, 132–3, 133f
  flow misregistration artifact, 104, 105f, 106f
fluid-attenuated inversion recovery (FLAIR), 81
fMRI. See functional MRI (fMRI)
Food and Drug Administration (FDA)
on MRI safety, 196
4D time-resolved MR angiography with keyhole (4D-TRAK), 138
4D-TRAK (4D time-resolved MR angiography with keyhole), 138
Fourier imaging
  partial, 53, 53f
  Fourier transformation, 103, 169, 171–3, 171f, 172f, 174f, 175f
  FOV. See field of view (FOV)
free induction decay (FID), 12–13, 13f
frequency encoding, 30–2, 31f, 32f
frequency selective pulses
  in RV waveform characterization, 41–4, 42f, 43f
  frequency selective saturation, 99–101, 99f, 100f
  full-width at half-maximum height (FWHM), 165
  functional brain imaging, 156–7
  functional MRI (fMRI), 156–7
  functional MRI (fMRI) studies
    BOLD, 157
FWHM. See full-width at half-maximum height (FWHM)

G
gadolinium-based contrast agents (GBCAs)
  in MRI, 190–3, 191f, 192t–3t
  gating
    in motion artifact reduction, 127–32, 130f, 131f
  Gaussian pulses
  in RV waveform characterization, 42, 43f
GBCAs. See gadolinium-based contrast agents (GBCAs)
Generalized Autocalibrating Partially Parallel Acquisition (GRAPPA), 63–4, 64f
GMR. See gradient motion rephasing (GMR)
gradient(s), 182
  safety precautions related to, 198
gradient coil
  actively shielded, 184
  gradient echo sequences, 70–5, 71t, 72f–5f. See also specific types
  absence of 180° RF pulse in, 70–1, 71t
  acronyms for, 71t
  described, 70
  MP pulses incorporated into, 82–5, 83f–5f
    refocused, 71t, 72–5, 72f–5f. See also refocused gradient echo sequences
  spoiled, 71–2, 71t
  steady-state, 71t, 72–5, 72f–5f
  types of, 71–5, 71t, 72f–5f
  gradient fields, 26–8, 27f, 182
  gradient motion rephasing (GMR), 132–3, 133f
  gradient pulses, 183
  gradient system
    in MRI system, 178f, 182–4, 188
    GRAPPA (Generalized Autocalibrating Partially Parallel Acquisition), 63–4, 64f
  great vessels
    MRI applications in, 210–11, 211f, 212f

H
  hard pulses, 41, 41f
  heart
    MRI applications in, 210–11, 211f, 212f
  Hermitian symmetry, 53
  hydrogen MRS, 162–76. See also magnetic resonance spectroscopy (MRS)
  hyperbolic secant pulses
    in RV waveform characterization, 42, 43f

I
IEC. See International Electrotechnical Commission (IEC)
image-based parallel techniques, 62, 63f
image contrast
  measurement parameters and, 86–93
image data matrices
  raw data in, 46–7, 46f, 47f
image processing computer
  in MRI system, 178, 178f
instrumentation, 177–88. See also specific components and magnetic resonance imaging (MRI) system
International Electrotechnical Commission (IEC)
on MRI safety, 196
intravenous agents
  in MRI, 190–5, 191f, 192t–3t, 194f
intravoxel incoherent motion, 148–9
intrinsic parameters, 87–9, 87f–9f
  effects of, 92t
  variables in, 92–3
  intrinsic variables, 92–3
inversion recovery (IR) looping modes, 79f, 80
inversion recovery (IR) pulse sequences, 78–80, 78f, 78t
  acronyms for, 78t
  image reconstruction process in, 80, 81f, 82f
inversion time (TI), 88–9, 89f
IR. See inversion recovery (IR)
### J

- **J coupling**  
  - in MRS, 164–5, 166f

### K

- **k-space**  
  - raw data and, 48–50, 49f, 51f  
  - k-space filling techniques, 51–8  
  - reduced, 51–3, 52f, 53f  
  - reordered, 54–5, 54f–6f  
  - types of, 56–8, 57f–9f  
  - k-space formalism, 49–50, 51f  
  - k-space trajectory, 54–5, 54f–6f  
  - k-space-based techniques  
    - GRAPPA, 63–4, 64f  
    - parallel, 62, 63f  
    - SMASH, 63–4  
    - SNR in, 64  
  - kidney(s)  
    - MRI applications in, 215, 216f  
  - knee  
    - MRI applications in, 207f, 208f

### L

- **Larmor equation**, 6, 27  
- **Larmor precession**, 4–6, 5f  
- **liver**  
  - MRI applications in, 211–15, 213f, 214f  
  - localization techniques  
    - in MRS, 167–9, 168f  
  - loop(s)  
    - sequence, 35–8, 36f, 37f

### M

- **magnet(s)**  
  - in MRI system, 178f, 180–2, 187  
  - magnet system, 178f, 180–2, 187  
  - magnetic field(s), 1–2  
  - magnetic field distortions, 120–2, 121f, 122f  
  - magnetic field gradients, 26–7, 27f  
  - magnetic resonance (MR)  
    - chemical shift in, 14–16, 15f, 16f  
    - concepts of, 10–16  
    - described, 1  
    - RF excitation in, 10–12, 11f  
    - RF signal detection in, 12–14, 13f, 14f  
  - magnetic resonance angiography (MRA), 135–46  
  - approaches to, 135–46  
  - described, 135–6  
  - flow selection in, 135, 136f  
  - MIP, 144–6, 145f, 146f  
  - phase contrast, 141–4, 143f–4f  
  - problems associated with, 136  
  - techniques, 135–46  
  - time-of-flight, 137–40, 137f–42f  
  - magnetic resonance imaging (MRI)  
    - advanced imaging applications for, 147–61. See also specific types and advanced imaging applications  
    - in agitated patients, 221  
    - artifacts in images, 103–25. See also artifact(s)  
    - clinical applications of, 200–21. See also clinical applications  
    - composite pulses in, 44–5, 45f  
    - confusing aspects of, 65  
    - contrast agents in, 189–95. See also contrast agents  
    - data collection methods, 54–5, 54f–6f  
    - functional, 156–7  
    - gradient fields in, 26–8, 27f  
    - initial step in, 28  
    - k-space filling techniques in, 51–8. See also k-space filling techniques  
    - nonrectilinear sampling in, 56  
    - parallel acquisition methods in, 60–4, 63f, 64f  
    - phase encoding in, 33–5, 33f, 34f  
    - phased-array coils in, 58–9, 60f, 61f  
    - principles of, 26–64  
    - projection reconstruction in, 57, 58f  
    - pulse sequences in, 65–85. See also pulse sequence(s)  
    - radial scanning in, 57, 58f  
    - ramped sampling in, 56–7, 57f  
    - raw data in  
      - image data matrices and, 46–7, 46f, 47f  
      - k-space and, 48–50, 49f, 51f  
      - readout or frequency encoding in, 30–2, 31f, 32f  
      - reduced k-space techniques in, 51–3, 52f, 53f  
      - reordered k-space filling techniques in, 54–5, 54f–6f  
      - RF selective excitation in, 39–44, 41f–3f  
      - safety precautions in, 196–9. See also safety precautions  
      - in sedated patients, 221  
      - sequence looping in, 35–8, 36f, 37f  
      - slice selection in, 28–9, 28f–30f  
      - SNR and tradeoffs in, 47–8  
      - two-dimensional spiral sampling in, 58, 59f  
  - magnetic resonance imaging (MRI) protocols  
  - principles in development of, 200  
  - magnetic resonance imaging (MRI) system, 177–88. See also specific components  
  - actively shielded gradient coil, 184  
  - components list, 187–8  
  - computer systems, 177–80, 178f, 187  
  - data acquisition system, 178f, 186–8  
  - diagram of, 178f  
  - gradient system, 178f, 182–4, 188  
  - magnet system, 178f, 180–2, 187  
  - RF transmitter system, 178f, 184–6, 185f, 188  
  - magnetic resonance (MR) signal, 12, 13f  
  - magnetic resonance spectroscopy (MRS), 162–76  
    - chemical shift in, 162–4, 163f, 164f  
    - concepts, 162–7, 163f, 164f, 166f  
    - hydrogen, 162–76  
    - localization techniques, 167–9, 168f  
    - multiple voxel techniques, 169, 170f  
    - single voxel techniques, 167–9, 168f  
    - spectral analysis and postprocessing steps, 169, 171–3, 171f, 172f, 174f, 175f  
    - spectral linewidth in, 163f, 165–7, 166f  
    - spin coupling in, 164–5, 166f  
    - SVS in, 167–9, 168f

---

### Index

- See also specific components
ultra-high field spectroscopy, 173, 175–6, 176f
magnetic susceptibility, 8–9
magnetic susceptibility difference artifact, 117, 118f, 120–1, 121f
magnetization materials susceptibility and, 8–9
magnetization-prepared (MP) pulses incorporated into gradient echo and EPI sequences, 82–5, 83f–5f
magnetization-prepared (MP) sequences, 77–85, 78f, 79f, 81f–4f
example of, 78, 78f, 79t
magnetization transfer (MT) pulse, 96
in time-of-flight MRA, 138
magnetization transfer (MT) suppression, 96–9, 97f, 98f
MAST. See motion artifact suppression techniques (MAST)
maximum intensity projection (MIP)
MRA–related, 144–6, 145f, 146f
maximum signal content site of, 48
measurement controller in MRI system, 178, 178f
measurement hardware as artifact, 122–4
measurement parameters, 86–93
extrinsic parameters, 89–91, 90f
effects of, 92t
intrinsic parameters, 87–9, 87f–9f
effects of, 92t
modification of, 86
parameter tradeoffs, 91–3, 92t
measurement protocol criteria in determining, 91–2
measurement techniques differentiating, 35–7
MIP. See maximum intensity projection (MIP)
modulation in RV waveform characterization, 40
motion Brownian, 147
intravoxel incoherent, 148–9
motion artifact(s), 103–5, 105f, 106f
appearance of, 104
causes of, 103–4
flow misregistration artifact, 104, 105f, 106f
respiratory, 104–5, 106f
types of, 104, 105f, 106f
motion artifact reduction techniques, 126–34
acquisition parameter modification, 126–7, 127f, 128f
flow compensation, 132–3, 133f
radial-based motion compensation, 134, 134f
triggering gating, 127–32, 130f, 131f
motion artifact suppression techniques (MAST) in motion artifact reduction, 132–3, 133f
MP sequences. See magnetization-prepared (MP) sequences
MR. See magnetic resonance (MR)
MRA. See magnetic resonance angiography (MRA)
MRI. See magnetic resonance imaging (MRI)
MRS. See magnetic resonance spectroscopy (MRS)
MT. See magnetization transfer (MT)
multiecho spin echo sequences, 67, 68f
multiple voxel techniques in MRS, 169, 170f
musculoskeletal system
MRI applications in, 206, 207f–9f
N
nature of synthesizer mixing
in RV waveform characterization, 40
neck
safety precautions related to, 204–5
negative agents in MRI, 193
net magnetization described, 6–7, 7f, 8f
production of, 1–9
NMR. See nuclear magnetic resonance (NMR)
noble gas imaging, 159–61, 160f
noise as artifact, 123f–4f, 124–5
nonrectilinear sampling, 56
nonsaturation methods, 101–2, 101f, 102f
nonselective pulses in RV waveform characterization, 41, 41f
nuclear magnetic moments, 3f, 4
nuclear magnetic resonance (NMR), 1
nuclear spin, 2–4, 3f, 3t, 5f
nucleus(i)
spin of, 2–4, 3f, 3t
null time for tissue, 80
Nyquist frequency, 14, 32
O
oral agents in MRI, 195
out-of-phase gradient echo clinical applications for, 219
oversampling, 91
effects of, 107, 107f
P
PACS (picture archiving and communications system) unit, 178–9
parallel acquisition methods, 60–4, 63f, 64f
requirements for, 62, 64f
types of, 62, 63f
partial Fournier imaging, 53, 53f
pelvis MRI applications in, 215, 217, 217f, 218f
Perflubron (perfluorocyclylbromide [PFOB]), 195
perfluorocyclylbromide (PFOB), 195
perfusion, 153–5, 154f–6f
perfusion blood flow in diffusion measurement, 148–9
perfusion studies approaches to, 153
applications of, 154–5, 154f–6f
PFOB. See perfluorocyclylbromide (PFOB)
PGSE. See pulsed gradient spin echo (PGSE) method
Index

phase
  in RV waveform characterization, 40
phase cancellation artifact, 110–11, 111f, 111r
phase contrast MRA, 141–4, 143f–4f
phase encoding
  in MRS, 33–5, 33f, 34f
  phased-array coils, 58–9, 60f, 61f
picture archiving and communications system (PACS) unit, 178–9
point resolved spectroscopy (PRESS), 167–9, 168f
postprocessing
  in MRS, 169, 171–3, 171f, 172f, 174f, 175f
pregnancy
  MRI during, 196
PRESS. See point resolved spectroscopy (PRESS)
projection reconstruction, 57, 58f
PROPELLER, 134, 134f
PSAL. See pulsed arterial spin labeling (PSAL)
pseudodiffusion, 149
pulse(s)
  composite, 44–5, 45f
  frequency selective, 41–4, 42f, 43f, 99–101, 99f, 100f
  frequency selective soft, 41–4, 42f, 43f
  Gaussian, 42, 43f
  gradient, 183
  hard, 41, 41f
  hyperbolic secant, 42, 43f
  MP
    incorporated into gradient echo and EPI sequences, 82–5, 83f–5f
    MT, 96–9, 97f, 98f
  in time-of-flight MRA, 138
  nonselective, 41, 41f
  in RV waveform characterization, 41, 41f
  RF excitation, 44
  in RV waveform characterization, 39–44, 41f–3f.
  See also specific types
  sinc, 41–2, 42f, 43f
  soft, 41–4, 42f, 43f
  spatial presaturation, 94–6, 95f
pulse sequence(s), 65–85. See also specific types
  comparison of, 65–7, 66f
  defined, 65
  EPI sequences, 75–7, 76f
  gradient echo sequences, 70–5, 71f, 72f–5f
  implementation of, 65
  IR pulse sequences, 78–80, 78f, 78t
  MP sequences, 77–85, 78f, 78t, 79f, 81f–4f
  spin echo sequences, 67–70, 67f, 68f, 69f
  timing diagrams in comparison of, 66–7, 66f
pulse shape
  in RV waveform characterization, 41, 41f
  pulsed arterial spin labeling (PSAL), 153
  pulsed gradient spin echo (PGSE) method, 148, 148f

R
radial artifact, 119, 120f
radial-based motion compensation
  in motion artifact reduction, 134, 134f
  radial scanning, 57, 58f
radiofrequency (RF) excitation
  in MR, 10–12, 11f
  selective, 39–44, 41f–3f
radiofrequency (RF) excitation pulses criteria for, 44
radiofrequency (RF) power deposition
  safety precautions related to, 198–9
radiofrequency (RF) signal detection
  in MR, 12–14, 13f, 14f
radiofrequency (RF) transmitter system
  in MRI system, 178f, 184–6, 185f, 188
radiofrequency (RF) waveform
  parameters in characterizing, 39–44, 41f–3f
  ramped sampling, 56–7, 57f
  raw data, 46–7, 46f, 47f
  k-space and, 48–50, 49f, 51f
  readout, 30–2, 31f, 32f
  reduced k-space techniques, 51–3, 52f, 53f
  refocused gradient echo sequences, 71f, 72–5, 72f–5f
  described, 72
  signals measured from, 73–5, 73f, 74f
relaxation, 17–25
  defined, 17
  spin–spin, 21–2, 21f
  T1
  saturation and, 17–21, 18f–20f
  T2, 21–5, 21f, 22f, 25f
  T2*, 22f, 23–4, 25f
relaxation agents
  in MRI. See specific agents and contrast agents
reordered k-space filling techniques, 54–5, 54f–6f
repetition time (TR), 87, 87f
respiratory motion artifact, 104–5, 106f
RF. See radiofrequency (RF)
rise time, 183

S
safety precautions, 196–9
  base magnetic field, 197
  contrast agents, 199
  cryogens, 197–8
  FDA on, 196
  gradients, 198
  IEC on, 196
  pregnancy-related, 196
  RF power deposition, 198–9
saturation
  T1 relaxation and, 17–21, 18f–20f
scanner controller
  in MRI system, 177–8, 178f
  “schimming,” 122
sedated patients
  MRI in, 221
“seed” region, 146
Send/Receive, 180
sequence looping, 35–8, 36f, 37f
sequence protocol–related artifacts, 105, 107–19
  aliasing, 105, 107–8, 107f–10f
  chemical shift artifacts, 108–10, 109f
  coherence artifacts, 113, 115–17, 115f–18f
magnetic susceptibility difference artifact, 117, 118f
phase cancellation artifact, 110–11, 111f, 111r
radial artifact, 119, 120f
truncation artifacts, 112, 112f–14f
shoulder
MRI applications in, 209f
signal suppression techniques, 94–102
Dixon method, 102, 102f
frequency selective saturation, 99–101, 99f, 100f
MT suppression, 96–9, 97f, 98f
nonsaturation methods, 101–2, 101f, 102f
spatial presaturation, 94–6, 95f
water excitation, 101, 101f
signal-to-noise ratio (SNR), 14
increase in, 91
k-space–based techniques, 64
in parallel acquisition methods, 61–2
tradeoffs, 47–8
Simultaneous Acquisition of Spatial Harmonics (SMASH), 63–4
sinc pulses
in RV waveform characterization, 41–2, 42f, 43f
single-echo spin echo sequence, 67, 68f
clinical applications for, 218–19
single voxel spectroscopy (SVS)
in MRS, 167–9, 168f
single voxel techniques
in MRS, 167–9, 168f
slice gap, 89–90, 90f
slice selection
in MRI, 28–9, 28f–30f
slice thickness (TH), 89
SMASH (Simultaneous Acquisition of Spatial Harmonics), 63–4
SNR. See signal-to-noise ratio (SNR)
splines
in RV waveform characterization, 41–4, 42f, 43f
spatial presaturation, 94–6, 95f
spatial presaturation pulse, 94–6, 95f
spectral analysis
in MRS, 169, 171–3, 171f, 172f, 174f, 175f
spectral linewidth
in MRS, 163f, 165–7, 166f
spike(s)
defined, 123f, 125
spin coupling
in MRS, 164–5, 166f
spin echo(es), 21–5, 21f, 22f, 25f
spin echo sequences, 67–70, 67f, 68f, 69f. See also specific types
acronyms for, 67f
ETSE, 69–70, 69f
multiecho, 67, 68f
single-echo, 67, 68f
types of, 67–8, 67t
spin echo–based sequences, 82–3
spine
MRI applications in, 205–6, 205f, 206f
spin–spin relaxation, 21–2, 21f
SPIO. See superparamagnetic iron oxide (SPIO)
spoiled gradient echo
clinical applications for, 219
spoiled gradient echo sequences, 71–2, 71f
standard multiecho spin echo
clinical applications for, 220
steady-state gradient echo sequences, 71t, 72–5, 72f–5f. See also refocused gradient echo sequences
STEAM. See stimulated echo acquisition method (STEAM)
Stejskal–Tanner method, 148, 148f
stimulated echo acquisition method (STEAM), 167–8, 168f
STIR imaging
clinical applications for, 220
stroke
diffusion-weighted imaging in evaluation of, 151–3
subloop(s)
in sequence looping, 35–6
superparamagnetic iron oxide (SPIO) particulate molecules, 194–5, 194f
surface coils, 59, 60f
susceptibility
bulk magnetic, 8–9
magnetic, 8–9
magnetization materials and, 8–9
SVS. See single voxel spectroscopy (SVS)
T
TCP/IP (Transmission Control Protocol/Internet Protocol)
in MRI system, 179
TE. See echo time (TE)
TH. See slice thickness (TH)
thorax
MRI applications in, 205–6
TI. See inversion time (TI)
time-of-flight MRA, 137–40, 137f–42f
time-resolved angiography with interleaved stochastic trajectories (TWIST), 138
time-resolved imaging of contrast kinetics (TRICKS), 138
timing diagram
in pulse sequence comparison, 66–7, 66f
T1 relaxation
defined, 17
saturation and, 17–21, 18f–20f
TI relaxation agents
in MRI, 190–3, 191f, 192r–3r
T1-weighted imaging studies
in perfusion studies, 153
T1-weighted techniques
clinical applications for, 218–20. See also specific techniques
fat saturation
clinical applications for, 219–20
TR. See repetition time (TR)
Transmission Control Protocol/Internet Protocol (TCP/IP)
in MRI system, 179
TRICKS (time-resolved imaging of contrast kinetics), 138
Index

trig**ering gating**
  in motion artifact reduction, 127–32, 130f, 131f
truncation artifacts, 112, 112f–14f

*T2 effects*
  in diffusion measurement, 149, 150f
*T2 relaxation*, 21–5, 21f, 22f, 25f
*T2*+ relaxation, 22f, 23–4, 25f
defined, 23

*T2 relaxation agents*
  in MRI, 194–5, 194f
*T2-weighted imaging studies*
  in perfusion studies, 153
*T2-weighted techniques*
  clinical applications for, 220–1
  fat saturation
  clinical applications for, 221
turbo factor, 88

TWIST (time-resolved angiography with interleaved stochastic trajectories), 138
two-dimensional spiral sampling, 58, 99f

**U**
ultra-high field imaging, 158–9
ultra-high field spectroscopy
  in MRS, 173, 175–6, 176f

**W**
water excitation
  for signal suppression, 101, 101f
water suppression
  in MRS, 167

**Z**
Zeeman interaction, 6–7, 7f
zero filling, 171, 171f